Combioxin

Executive Summary

Combioxin is a Swiss biotech company developing CAL02, a first-in-class, broad-spectrum anti-virulence agent for severe community-acquired bacterial pneumonia (SCAP). CAL02 targets bacterial toxins, neutralizing them regardless of pathogen species, offering a novel approach that could address rising antibiotic resistance. The company completed a Phase 1 trial (NCT02583373) in 2018, evaluating low- and high-dose CAL02 plus placebo in pneumonia patients. Results demonstrated a favorable safety profile and suggested potential clinical benefit, with reduced organ failure biomarkers. However, the company has not publicly announced subsequent clinical progression or partnerships. SCAP remains a high-mortality condition with limited therapeutic options, positioning CAL02 as a potentially disruptive therapy if it advances to later-stage trials. As a private, early-stage company, Combioxin relies on external funding or licensing deals to progress. The lack of recent public updates increases uncertainty, but the platform’s novelty and unmet need warrant continued monitoring.

Upcoming Catalysts (preview)

• Q4 2027Initiation of Phase 2 trial for CAL02 in SCAP20% success
• TBDPublication of full Phase 1 results in peer-reviewed journal80% success
• Q4 2027Partnership or licensing agreement for CAL02 development25% success